Compounds and methods of use

US8114893B2 · kind B2 · utility

Assignees

• Genentech, Inc. · US
• Abbott Laboratories · US
• The Walter and Eliza Hall Medical Research Institute · AU

Inventors

• Jonathan Bayldon Baell · Ivanhoe, AU
• Chinh Thien Bui · Melbourne, AU
• Peter Colman · Melbourne, AU
• Danette Dudley · Ann Arbor, US
• Wayne Fairbrother · South San Francisco, US
• John A. Flygare · Burlingame, US
• Guillaume Laurent Lessene · Melbourne, AU
• Chudi Ndubaku · Oakland, US
• George Nikolakopoulos · Melbourne, AU
• Carl Rye · Royal Sutton Coldfield, GB
• Brad Sleebs · Morgan, AU
• Brian John Smith · Melbourne, AU
• Keith G. Watson · Melbourne, AU
• Steven W. Elmore · Northbrook, US
• Andrew M. Petros · Mundelein, US
• Andrew J. Souers · Libertyville, US
• Peter Edward Czabotar · Melbourne, AU

Key dates

• Filing date: Dec 17, 2009
• Grant date: Feb 14, 2012
• Expiry date: Dec 17, 2029

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D487/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

In one aspect, the present invention provides for a compound of Formula Iin which in Formula I, the variables X1, X2a, X2b, X2c, R1, B, L, E, A and the subscript n are as defined herein. In another aspect, the present invention provides for pharmaceutical compositions comprising compounds of Formula I as well as methods for using compounds of Formula I for the treatment of diseases and conditions (e.g., cancer, thrombocythemia, etc) characterized by the expression or over-expression of Bcl-2 anti-apoptotic proteins, e.g., of anti-apoptotic Bcl-xL proteins.